Skip to main navigation Skip to search Skip to main content

Durvalumab with or Without Tremelimumab for Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial

  • Eileen M. O'Reilly
  • , Do Youn Oh
  • , Neesha Dhani
  • , Daniel J. Renouf
  • , Myung Ah Lee
  • , Weijing Sun
  • , George Fisher
  • , Aram Hezel
  • , Shao Chun Chang
  • , Gordana Vlahovic
  • , Osamu Takahashi
  • , Yin Yang
  • , David Fitts
  • , Philip Agop Philip
  • Memorial Sloan-Kettering Cancer Center
  • Seoul National University
  • Ontario Cancer Institute
  • Provincial Health Services Authority
  • University of Kansas
  • Stanford University
  • University of Rochester
  • AstraZeneca
  • Independent Biostatistician
  • Wayne State University

Research output: Contribution to journalArticlepeer-review

623 Scopus citations

Fingerprint

Dive into the research topics of 'Durvalumab with or Without Tremelimumab for Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science